WO2003009870A1 - Remedes traitant le cancer du sein - Google Patents

Remedes traitant le cancer du sein Download PDF

Info

Publication number
WO2003009870A1
WO2003009870A1 PCT/JP2002/007548 JP0207548W WO03009870A1 WO 2003009870 A1 WO2003009870 A1 WO 2003009870A1 JP 0207548 W JP0207548 W JP 0207548W WO 03009870 A1 WO03009870 A1 WO 03009870A1
Authority
WO
WIPO (PCT)
Prior art keywords
remedies
mammary cancer
hyper
seq
nos
Prior art date
Application number
PCT/JP2002/007548
Other languages
English (en)
French (fr)
Inventor
Saiko Hosokawa
Hisae Niki
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Priority to JP2003515262A priority Critical patent/JPWO2003009870A1/ja
Priority to EP02751683A priority patent/EP1410806A4/en
Priority to CA002454667A priority patent/CA2454667A1/en
Priority to US10/483,993 priority patent/US20050037061A1/en
Publication of WO2003009870A1 publication Critical patent/WO2003009870A1/ja
Priority to US11/863,679 priority patent/US20080241161A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/JP2002/007548 2001-07-25 2002-07-25 Remedes traitant le cancer du sein WO2003009870A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003515262A JPWO2003009870A1 (ja) 2001-07-25 2002-07-25 乳癌治療薬
EP02751683A EP1410806A4 (en) 2001-07-25 2002-07-25 REMEDIES FOR BREAST CANCER
CA002454667A CA2454667A1 (en) 2001-07-25 2002-07-25 Remedies for mammary cancer
US10/483,993 US20050037061A1 (en) 2001-07-25 2002-07-25 Remedies for mammary cancer
US11/863,679 US20080241161A1 (en) 2001-07-25 2007-09-28 Remedy for mammary cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-224596 2001-07-25
JP2001224596 2001-07-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/863,679 Division US20080241161A1 (en) 2001-07-25 2007-09-28 Remedy for mammary cancer

Publications (1)

Publication Number Publication Date
WO2003009870A1 true WO2003009870A1 (fr) 2003-02-06

Family

ID=19057728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007548 WO2003009870A1 (fr) 2001-07-25 2002-07-25 Remedes traitant le cancer du sein

Country Status (5)

Country Link
US (2) US20050037061A1 (ja)
EP (1) EP1410806A4 (ja)
JP (1) JPWO2003009870A1 (ja)
CA (1) CA2454667A1 (ja)
WO (1) WO2003009870A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452597A1 (en) * 2001-12-04 2004-09-01 Mitsubishi Pharma Corporation Method of activating protein
WO2004089419A1 (ja) * 2003-04-04 2004-10-21 The University Of Tokyo 抗ｍｔ－ｍｍｐモノクローナル抗体含有脂質膜構造体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454515A1 (en) * 2001-07-25 2003-02-06 Mitsubishi Pharma Corporation Cancer diagnostics
WO2006030602A1 (ja) * 2004-09-16 2006-03-23 Mitsubishi Pharma Corporation 卵巣癌の診断および／または治療薬
JP5110880B2 (ja) * 2004-11-18 2012-12-26 テルモ株式会社 医薬組成物、製剤および組み合わせ製剤
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20070292497A1 (en) * 2006-05-04 2007-12-20 Martin Francis J Method for treating micrometastatic tumors
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
BRPI0913612B8 (pt) * 2008-06-05 2021-05-25 Immunovaccine Technologies Inc composição injetável de vacina, método para obter a composição e uso da composição
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
US10096110B2 (en) * 2014-08-22 2018-10-09 University Of South Florida System and method for automated stereology of cancer
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520499A1 (en) * 1991-06-28 1992-12-30 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
WO1999055367A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California INTERNALIZING ErbB2 ANTIBODIES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US6787153B1 (en) * 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JP4111368B2 (ja) * 1999-04-23 2008-07-02 三菱化学株式会社 抗体およびポリアルキレングリコール結合リポソーム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520499A1 (en) * 1991-06-28 1992-12-30 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
WO1999055367A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California INTERNALIZING ErbB2 ANTIBODIES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASAKI DOI: "Adriamycin to monoclonal kotai A7 tono fukugotai no sakusei to hito nyugan eno oyo", JOURNAL OF KYOTO PREFECTURAL UNIVERSITY OF MEDICINE, vol. 106, no. 11, 25 November 1997 (1997-11-25), pages 1049 - 1057, XP002961358 *
PAPAHADJOPOULOS DEMETROIS ET AL.: "Targeting of drugs to solid tumors using anti-HER2 immunoliposomes", JOURNAL OF LIPOSOME RESEARCH, vol. 8, no. 4, 1 November 1998 (1998-11-01), pages 425 - 442, XP000790300 *
SAIKO HOSOKAWA ET AL.: "Biotechnology to kagaku no yugo -gan targeting ryohozai no kaihatsu kenkyu-", THE AROMATICS, vol. 48, no. 5-6, 15 May 1996 (1996-05-15), pages 143 - 155, XP002961359 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452597A1 (en) * 2001-12-04 2004-09-01 Mitsubishi Pharma Corporation Method of activating protein
EP1452597A4 (en) * 2001-12-04 2006-09-20 Mitsubishi Pharma Corp PROTEIN ACTIVATION METHOD
WO2004089419A1 (ja) * 2003-04-04 2004-10-21 The University Of Tokyo 抗ｍｔ－ｍｍｐモノクローナル抗体含有脂質膜構造体
JPWO2004089419A1 (ja) * 2003-04-04 2006-07-06 国立大学法人 東京大学 抗ｍｔ−ｍｍｐモノクローナル抗体含有脂質膜構造体

Also Published As

Publication number Publication date
US20080241161A1 (en) 2008-10-02
JPWO2003009870A1 (ja) 2004-11-11
CA2454667A1 (en) 2003-02-26
US20050037061A1 (en) 2005-02-17
EP1410806A1 (en) 2004-04-21
EP1410806A4 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
WO2003009870A1 (fr) Remedes traitant le cancer du sein
WO2003059951A3 (fr) Anticorps anti-igf-ir et leurs applications
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
WO2005058967A3 (en) Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
IL157446A0 (en) Increased recovery of active proteins
WO1999066951A3 (en) Use of bi-specific antibodies for pre-targeting diagnosis and therapy
WO2005003170A3 (en) Modified antibody fragments
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
HK1023513A1 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
WO2003011878A3 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
EP1808155A3 (en) Antibody-serum protein hybrids
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
TW200510528A (en) Polypeptide inducing apoptosis
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
WO2002018443A3 (en) A recombinant monoclonal antibody to phosphotyrosine-containing proteins
ATE464383T1 (de) Tumor antigen
EP2641611A3 (en) Combination therapy
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003515262

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002751683

Country of ref document: EP

Ref document number: 2454667

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002751683

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10483993

Country of ref document: US